Axol Bioscience, a provider of induced pluripotent stem cell (iPSC), has secured £2 million in funding led by US life sciences specialist BroadOak Capital Partners, with participation from the company’s founding investor, the Roslin Foundation.
The investment will accelerate Axol’s next phase of growth by expanding its US operations and commercial presence. It will also enable the development of enhanced neuroscience, ophthalmology and cardiovascular disease models, alongside cell manufacturing scale-up at its Roslin Innovation Centre base, in response to increasing global customer demand for more human-relevant in vitro disease models.
Axol develops and supplies functional iPSC-derived cells and services to pharmaceutical, biotech, CRO and academic institutions worldwide. It has established itself in the provision of physiologically relevant iPSC-derived models for neurodegenerative disorders including Huntington’s disease and sporadic amyotrophic lateral sclerosis, addressing unmet needs in neurodegenerative disease research.
The funding comes amid increasing global demand for human-relevant cell-based models, with Axol reporting sustained double-digit revenue growth and continued expansion of its disease model portfolio. Over the past year, Axol has strengthened relationships with global pharmaceutical partners and advanced its US market presence, alongside continued investment in manufacturing and quality systems at its Edinburgh facility.
Axol reported 45% revenue growth in 2025 and 36% in 2024. The funding will be used to strengthen US operations and expand manufacturing capacity at its Edinburgh site to meet increasing global demand as the company scales operations and expands internationally.
